SC
AGIO icon

Stephens Consulting’s Agios Pharmaceuticals AGIO Stock Holding History

Stephens Consulting’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$440 – 1208
2025
Q1 		$440 Buy
+15
New +$498 ﹤0.01% 957
2024
Q3 		– Sell
-55
Closed -$2.37K – 518
2024
Q2 		$2.37K Buy
+55
New +$1.99K ﹤0.01% 493

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stephens Consulting's AGIO Position: Q2 2025 in Review

Stephens Consulting sold out of Agios Pharmaceuticals (AGIO) in Q2 2025, closing a stake of 15 shares — an estimated $440 sold.

Stephens Consulting first reported a position in AGIO in Q2 2024 and held it in 2 quarters. The position peaked at $2.37K in Q2 2024. 214 funds tracked by Wall St. Rank hold AGIO as of Q2 2025.

  • Stephens Consulting reported no remaining Agios Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 15 Agios Pharmaceuticals shares in Q2 2025, an estimated $440.
  • Stephens Consulting first reported a position in Agios Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Stephens Consulting's Agios Pharmaceuticals position peaked at $2.37K in Q2 2024.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.